Bayer Prices Stivarga With Crowded Colon Cancer Market In Mind
This article was originally published in The Pink Sheet Daily
Executive Summary
Ahead of schedule, FDA approves Stivarga (regorafenib), partnered with Onyx, for late-stage mCRC patients with few options left. Bayer prices drug at under $10,000 a month, on par with competing treatments.
You may also be interested in...
Market Snapshot: Zaltrap Changes Cost-Benefit Expectations For New Colon Cancer Drugs
Lilly’s Cyramza, Boehringer Ingelheim’s Vargatef and Taiho’s TAS-102 will join an increasingly crowded and price sensitive market in metastatic colorectal cancer in the coming years.
Bayer Oncology Keystone Nexavar Looks Good For Thyroid Indication
Adding indications for Nexavar is critical to Bayer HealthCare’s plan to become a major global player in cancer therapeutics, Bayer oncology leader says at ASCO.
Bayer/Onyx Stick To Advanced Cancer Setting With Stivarga’s GIST Indication
New indication for third-line gastrointestinal stromal tumors, an area of high unmet need, builds on candidate’s initial approval in advanced colon cancer.